The most notable breakthrough is vorasidenib, a dual IDH1/2 inhibitor that achieved a landmark success in the phase III INDIGO trial, showing a clinically meaningful prolongation of progression-free survival (PFS) and delayed time to next intervention in patients with grade 2 IDH-mutant glioma [141]. The gene discussed is IDH2; the disease is central nervous system cancer.